E-cadherin/ROS1 inhibitor synthetic lethality in breast cancer

The cell adhesion glycoprotein E-cadherin (CDH1) is commonly inactivated in breast tumours. Precision medicine approaches that exploit this characteristic are not available. Using perturbation screens in breast tumour cells with CRISPR-Cas9 engineered CDH1 mutations, we identified synthetic lethalit...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Discov
Main Authors: Bajrami, Ilirjana, Marlow, Rebecca, van de Ven, Marieke, Brough, Rachel, Pemberton, Helen N., Frankum, Jessica, Song, Fei Fei, Rafiq, Rumana, Konde, Asha, Krastev, Dragomir B., Menon, Malini, Campbell, James, Gulati, Aditi, Kumar, Rahul, Pettitt, Stephen J., Gurden, Mark D., Cardenosa, Marta Llorca, Chong, Irene, Gazinska, Patrycja, Wallberg, Fredrik, Sawyer, Elinor J., Martin, Lesley-Ann, Dowsett, Mitch, Linardopoulos, Spiros, Natrajan, Rachael, Ryan, Colm J., Derksen, Patrick W.B., Jonkers, Jos, Tutt, Andrew N.J., Ashworth, Alan, Lord, Christopher J.
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6296442/
https://ncbi.nlm.nih.gov/pubmed/29610289
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-17-0603
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados